Merck & Co., Inc. is a global healthcare company focusing on prescription medicines, vaccines, and animal health products. With a market cap of $249.20 billion, it recently hit a 52-week high of $105.84 after outperforming its peers in the sector. The company’s stock has shown growth and stability over time.

Merck announced strong third-quarter results for fiscal 2025, with a 4% increase in sales to $17.28 billion, driven by growth in pharmaceutical segments like oncology and cardiovascular. The company’s adjusted EPS rose by 64% to $2.58, showing a positive outlook for future performance.

Comparing Merck’s performance to Pfizer Inc., Merck has shown better growth over the past 52 weeks and six months. Wall Street analysts have a “Moderate Buy” rating on Merck’s stock, with a mean price target of $104.83, indicating a slight downside, but a high target of $139 suggests a potential 31.6% upside.

Read more at Yahoo Finance: Is MRK Outperforming the Healthcare Sector?